Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel (NCT06824948) | Clinical Trial Compass
CompletedPhase 1
Evaluate the Safety, Tolerance, and Pharmacokinetic Profiles of Timolol Maleate Gel
China28 participantsStarted 2018-10-12
Plain-language summary
The goal of this clinical trial is to to evaluate the safety, tolerance, and pharmacokinetic profiles of Timolol Maleate Gel in healthy Chinese adult subjects. The main questions aim to answer are:
• The pharmacokinetic endpoints: Single dose:Tmax, Cmax, etc. Multiple doses:AUC0-t, AUC0-inf, λz, t1/2, etc.
• The safety and tolerance endpoints: Physical examination, vital signs, 12-lead ECG, laboratory tests (hematology, blood biochemistry and urinalysis), adverse events, local tolerance.
Researchers will compare TM gel to a placebo (a look-alike substance that contains no drug) to see if TM gel works to treat IH.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Healthy adult male or female subjects aged 18-55 years (including the cut point, subject to the time of signing the ICF);
✓. Subjects with the body mass index (BMI) of 19-26 kg/m2 (including the cut point), where the body weight should be ≥ 50 kg for male subjects and ≥ 45 kg for female subjects;
✓. Subjects who have no pregnancy plan, voluntarily adopt effective birth controls, and have no sperm donation or egg donation plan during the study until 3 months after the last dose. For specific birth controls, see Appendix 1: Birth Control, Definition of Female Subjects of Childbearing Age, and Contraception Requirements;
✓. Subjects fully understand the study objective, nature, methods and possible adverse reactions, voluntarily become subjects, and sign the ICFs;
✓. Subjects who have no skin damage or scar or skin disease at the administration site; Subjects who can complete the trial as required in the protocol.
Exclusion criteria
✕. Subjects who are allergic to timolol maleate and similar drugs;
✕. Subjects who have any difficulty in venous blood collection;
What they're measuring
1
Local tolerance
Timeframe: 13 Days
2
Adverse events
Timeframe: Throughout study completion, an average 13 days
3
Vital signs (blood pressure)
Timeframe: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.
4
Vital signs (temperature)
Timeframe: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.
5
Vital signs (pulse rate)
Timeframe: the screening phase, Day -1, Day 1, 3, 6, 9, 12, and Day 13.
6
Laboratory tests
Timeframe: the screening phase, the baseline phase, and on Days 6 and 13.
7
Physical examinations
Timeframe: the screening phase, baseline phase and on Day 13
8
12-lead ECG
Timeframe: the screening phase, baseline phase, Day 1, 3, 6, 9, 12, and Day 13.
✕. Subjects who have cardiogenic shock, Grade I or Grade III atrioventricular block, cardiac failure, sinus bradycardia, hypotension, and CS as assessed by the study physician;
✕. Subjects who have bronchial asthma, airway sensitive disease, ventilation difficult or other pulmonary disorders;
✕. Subjects who have had a history of drug abuse in the past five years or used drugs within the 3 months before the study; or subjects who are positive in the drug abuse screening test in the screening phase;
✕. Subjects who have smoked more than 5 cigarettes a day within the 3 months before screening;
✕. Subjects who have consumed more than 14 units of alcohol (1 unit of alcohol = 360 mL beer or 45 mL 40% spirits or 150 mL wine) weekly within 6 months before the screening or have taken alcohol-containing products 48 h pre-dose, or were or positive in the alcohol breath test in the screening phase and/or the baseline phase;
✕. Subjects who have used any drug that induces or inhibits liver metabolic enzymes within 28 days pre-dose in the study;